Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
In addition, azithromycin was associated with lower odds of BPD than hydrocortisone [OR = 0.26, 95% CrI: 0.05 to 0.98], ibuprofen [OR = 0.21, 95% CrI: 0.04 to 0.93], and vitamin D [OR = 0.12, 95% CrI: 0.02 to 0.59] (Supplementary Material 2, Table S4A).
Source: Primary outcome (BPD incidence). View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Review / evidence synthesis.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Efficacy of pharmacologic therapies for reducing bronchopulmonary dysplasia and mortality in preterm infants: a network meta-analysis
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Efficacy of pharmacologic therapies for reducing bronchopulmonary dysplasia and mortality in preterm infants: a network meta-analysis
Review / evidence synthesis · BMC Pediatrics · 2026
Original publication title
Efficacy of pharmacologic therapies for reducing bronchopulmonary dysplasia and mortality in preterm infants: a network meta-analysis
© The Author(s) 2026
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
This network meta-analysis aimed to summarize the comparative evidence for pharmacologic interventions evaluated for reducing BPD incidence and pre-discharge mortality in preterm infants.
Source: AimAbstract: What methods does the paper describe?
We searched PubMed, Embase, Cochrane Library, and Web of Science for randomized controlled trials (RCTs) investigating pharmacological therapies for BPD prevention, with a search cutoff of September 1, 2025. Data analysis was conducted using R 4.2.3 software. The primary outcome was BPD incidence, and the secondary outcome was pre-discharge mortality. BPD definitions and assessment timepoints were extracted from individual studies and interpreted considering variation across NIH 2001, NIH 2018, Shennan, or study-specific criteria.
Source: MethodsAbstract: Results
Thirty-six randomized controlled trials involving 11,414 preterm infants were included in the systematic review. Of these, 24 trials contributed to the BPD incidence network, and 19 trials contributed to the pre-discharge mortality network. Several interventions showed comparative signals for lower odds of BPD incidence or pre-discharge mortality when compared with placebo; however, the strength and precision of these signals varied across comparisons. In the BPD incidence network, some estimates excluded the null, but several comparisons were informed partly by indirect evidence or sparsely connected nodes.
In the pre-discharge mortality network, favorable estimates were less certain because mortality events were sparse and several 95% credible intervals (CrIs) were wide. The certainty of evidence was moderate for BPD incidence and low for pre-discharge mortality. SUCRA rankings were therefore interpreted only as probabilistic summaries within the network and not as evidence of clinical superiority.
Source: ResultsAbstract: Conclusion
This network meta-analysis identified several comparative signals for pharmacologic prevention of BPD and reduction of pre-discharge mortality in preterm infants. However, these findings are constrained by low-to-moderate certainty of evidence, indirect comparisons, sparse network nodes, and imprecision in several estimates. The results should therefore be interpreted as evidence-mapping and hypothesis-generating rather than as treatment recommendations. Future studies should prioritize direct head-to-head comparisons, phenotype: or severity-specific analyses, and long-term respiratory and neurodevelopmental outcomes.
Source: ConclusionAuthors’ abstract
Background
Bronchopulmonary dysplasia (BPD) is a major complication of prematurity and is associated with substantial respiratory morbidity, impaired growth, and increased mortality in severe cases. Pharmacologic prevention strategies have been evaluated in randomized trials, but their comparative effects remain uncertain.
Aim
This network meta-analysis aimed to summarize the comparative evidence for pharmacologic interventions evaluated for reducing BPD incidence and pre-discharge mortality in preterm infants.
Methods
We searched PubMed, Embase, Cochrane Library, and Web of Science for randomized controlled trials (RCTs) investigating pharmacological therapies for BPD prevention, with a search cutoff of September 1, 2025. Data analysis was conducted using R 4.2.3 software. The primary outcome was BPD incidence, and the secondary outcome was pre-discharge mortality. BPD definitions and assessment timepoints were extracted from individual studies and interpreted considering variation across NIH 2001, NIH 2018, Shennan, or study-specific criteria.
Results
Thirty-six randomized controlled trials involving 11,414 preterm infants were included in the systematic review. Of these, 24 trials contributed to the BPD incidence network, and 19 trials contributed to the pre-discharge mortality network. Several interventions showed comparative signals for lower odds of BPD incidence or pre-discharge mortality when compared with placebo; however, the strength and precision of these signals varied across comparisons. In the BPD incidence network, some estimates excluded the null, but several comparisons were informed partly by indirect evidence or sparsely connected nodes.
In the pre-discharge mortality network, favorable estimates were less certain because mortality events were sparse and several 95% credible intervals (CrIs) were wide. The certainty of evidence was moderate for BPD incidence and low for pre-discharge mortality. SUCRA rankings were therefore interpreted only as probabilistic summaries within the network and not as evidence of clinical superiority.
Conclusion
This network meta-analysis identified several comparative signals for pharmacologic prevention of BPD and reduction of pre-discharge mortality in preterm infants. However, these findings are constrained by low-to-moderate certainty of evidence, indirect comparisons, sparse network nodes, and imprecision in several estimates. The results should therefore be interpreted as evidence-mapping and hypothesis-generating rather than as treatment recommendations. Future studies should prioritize direct head-to-head comparisons, phenotype: or severity-specific analyses, and long-term respiratory and neurodevelopmental outcomes.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12887-026-07408-y.
Publication and source details
Original title: Efficacy of pharmacologic therapies for reducing bronchopulmonary dysplasia and mortality in preterm infants: a network meta-analysis
Runjia Zhao; Wei Guo
BMC Pediatrics · 2026
© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T22:02:09.893406+00:00
DOI: 10.1186/s12887-026-07408-y · PMC13504778